BioLight Life Sciences (XTAE:BOLT) ROCE % : -69.04% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is BioLight Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioLight Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -69.04%.

BioLight Life Sciences ROCE % Historical Data

The historical data trend for BioLight Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences ROCE % Chart

BioLight Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-18.33

-20.98

-3.04

-14.81

-64.03

BioLight Life Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															11.08	-15.92	-12.10	-15.91	-69.04

BioLight Life Sciences ROCE % Calculation

BioLight Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-27.41	/	( ( (57.011 - 2.536)	+	(33.452 - 2.315) )	/ 2 )
	=	-27.41	/	( (54.475	+	31.137)	/ 2 )
	=	-27.41	/	42.806
	=	-64.03 %

BioLight Life Sciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-43.046	/	( ( (93.569 - 0)	+	(33.452 - 2.315) )	/ 2 )
	=	-43.046	/	( ( 93.569	+	31.137 )	/ 2 )
	=	-43.046	/	62.353
	=	-69.04 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

BioLight Life Sciences (XTAE:BOLT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioLight Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (XTAE:BOLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (XTAE:BOLT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.